Related Experiment Video
Updated: Apr 20, 2026
Surgical Treatment of an Endolymphatic Sac Tumor
Published on: May 26, 2023
Bone-anchored hearing device placement with translabyrinthine tumor removal
Theodore R McRackan1, John C Goddard1, Eric P Wilkinson1
1House Clinic, Los Angeles, California, USA.
Objective:
Translabyrinthine resection of intracranial tumors results in single-sided deafness, which can be treated by surgical and nonsurgical means. Here we describe the first series examining complication and device usage rates among patients receiving a surgically implanted bone-anchored hearing device (BAHD) at the time of translabyrinthine tumor removal.
Study Design:
Case series with chart review.
Setting:
Private tertiary neurotologic referral center.
Patients:
Patients (N = 154) undergoing concurrent BAHD placement and translabyrinthine tumor resection.
Intervention:
Concurrent BAHD placement and translabyrinthine tumor removal.
Main Outcome Measures:
Postoperative complication rates and BAHD usage.
Results:
Of the 154 patients, 121 (78.6%) had no device-related complications. The most common device-related complications were skin overgrowth (8.4%), acute infection (5.2%), and chronic infection (3.2%). The overall and specific complication rates did not differ from published BAHD complication rates. One patient (0.6%) developed a cerebrospinal leak through the surgical site for the device. At the time of last follow-up (mean, 39.8 months), 151 patients (95.0%) were still using their devices.
Conclusion:
Patients undergoing concurrent translabyrinthine tumor removal and BAHD placement exhibit similar device-related complication profiles as patients undergoing standard device placement. Based on these outcomes and the high long-term usage rates, BAHD insertion at the time of translabyrinthine intracranial surgery can be considered a safe and useful procedure.
